Company Overview and News

19
Hong Kong, Chinese stocks slide on ZTE slump, rate rise fears

2018-06-13 scmp
The Hang Seng Index loses 1.22pc to end at 30,725.15. Market’s focus turns to potential interest rate increase by the US Federal Reserve on Thursday
0941 0762 CHLKF CHL CHUFF SOTGY TRI CHU 2382 SNPTF

0
Mainland and Hong Kong stocks rise in response to Trump-Kim summit

2018-06-12 scmp
‘Mood is still cautious’, however, as key economic data by China for May and interest rate increase by Fed also expected this week
SOTGY 2382 SNPTF

5
Unrelenting tech surge spurs Hong Kong’s benchmark higher

2018-06-06 scmp
Hong Kong’s stock market rose for a fifth straight session on Wednesday on the back of Nasdaq’s surge to another all-time high and Chinese telecoms company ZTE’s agreement to get the US ban lifted, extending gains in technology shares.
CHLLF 55BC SOTGY 2382 CBQS SNPTF AACAF CICHY 0700 CICHF AACAY CCB 0939

4
Chinese tech stocks surge after Nasdaq closes at all-time high

2018-06-05 scmp
Mainland Chinese and Hong Kong stocks closed higher on Tuesday, bolstered by the technology sector, after Apple, Amazon and Microsoft touched fresh records helping to push the Nasdaq to an all-time closing high overnight.
1336 2628 0700 SOTGY LFC 2382 SNPTF AACAY AACAF

0
Apple-linked shares gain after it unveils features aimed at taming user ‘addiction’, especially among younger customers

2018-06-05 scmp
Shares in Apple-related firms traded in Hong Kong and China climbed on Tuesday after the US tech giant soared to a record high overnight, due to strong investor reaction to a range of new software features revealed at its annual Worldwide Developer Conference
1415 SOTGY 2382 SNPTF

0
Hong Kong stocks plunge below 30,000 as Italy crisis rattles neves

2018-05-30 scmp
Hong Kong stocks plunged below the key 30,000 level on Wednesday morning for the first time in three weeks, joining a global equity sell-off after political turmoil in Italy shook financial markets across the globe and renewed US-China trade uncertainty rattled investors.
WHGRF SOTGY WHGLY 2382 SNPTF WGHPY

1
Apple supplier AAC Technologies slumps as brokers cut target price

2018-05-15 scmp
The maker of iPhone components was down more than 6 per cent after reporting disappointing profits for the first quarter
SOTGY 2382 SNPTF AACAY AACAF

2
Amid market decline, foreign investors chase China stocks and mainland traders sell Hong Kong shares

2018-04-19 scmp
Overseas investors bought China stocks for 13 consecutive days through Wednesday, while mainland traders sold Hong Kong shares for five days in a row
CICHY 55BC SOTGY CBQS 2382 CICHF SNPTF AACAY CCB AACAF 0939

12
Hong Kong stocks fall for first time in five days on fear of US tariffs on China tech sector

2018-03-14 scmp
Hong Kong’s benchmark stock index closed lower on Wednesday for the first time in five days, with electronics component suppliers posting heavy losses, in response to a report that US President Donald Trump is likely to impose tariffs on up to US$60 billion of Chinese imports in the tech and telecom sectors.
MS.PRI MS.PRK 2007 SOTGY MS.PRE MS.PRF MS.PRG MS MS.PRA 2382 SNPTF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

14h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

15h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...